Tuesday, March 13, 2012 3:12:46 PM
my thoughts..
1) i think it's obvious that their most likely will be a loss, due to kazzaa still being a burden on them.. but if they can show a turn around in revenues and expenses would that not be a positive sign? We can assume that because of all the DD being done abotu new clients, and Goldfarb said it himself that revenues would increase significantly. All the company needs to show is a turn around, or any positive signs of life that it wants to move upward, wether that be trimming expenses, or increasing revenues!
and we don't know if a merger or buy out is imminent, but the last time our ceo Fong went silent a merger did in facet take place!
1) i think it's obvious that their most likely will be a loss, due to kazzaa still being a burden on them.. but if they can show a turn around in revenues and expenses would that not be a positive sign? We can assume that because of all the DD being done abotu new clients, and Goldfarb said it himself that revenues would increase significantly. All the company needs to show is a turn around, or any positive signs of life that it wants to move upward, wether that be trimming expenses, or increasing revenues!
and we don't know if a merger or buy out is imminent, but the last time our ceo Fong went silent a merger did in facet take place!
Recent PTIX News
- Protagenic Therapeutics Completes Phytanix Separation, Strengthens Balance Sheet and Repositions the Company Around PT00114 • ACCESS Newswire • 03/17/2026 12:00:00 PM
- Protagenic Therapeutics Upgrades from OTC Pink to OTCQB Venture Market • ACCESS Newswire • 03/10/2026 12:00:00 PM
- Results from Phase 1 Multiple-Dose Study of PT00114 • ACCESS Newswire • 12/09/2025 01:46:00 PM
- Protagenic Therapeutics Announces Receipt of Nasdaq Non-Compliance Notice • ACCESS Newswire • 11/27/2025 08:45:00 AM
- Protagenic Therapeutics Announces Completion of Enrollment and Dosing in Phase 1 MAD Study • ACCESS Newswire • 11/13/2025 01:22:00 PM
- Protagenic Therapeutics Announces Grant of new patent in Japan for its Modified Stilbenoid Program Drug Candidates • GlobeNewswire Inc. • 07/30/2025 12:30:00 PM
- Nasdaq Top 5 Premarket Losers • IH Market News • 05/20/2025 12:47:37 PM
- Protagenic Therapeutics Soars 190% on Merger to Launch Neuroactive Biopharma Firm • IH Market News • 05/19/2025 02:28:09 PM
- Nasdaq Top 5 Premarket Gainers • IH Market News • 05/19/2025 01:07:08 PM
